Sun’s Ilumya Set For Phase III In Psoriatic Arthritis After ‘Promising’ Results
Sun releases what it says are promising interim data from a Phase II study on Ilumya, its flagship first novel biologic, in the additional indication of psoriatic arthritis, where the antibody met the primary endpoint in its first trial in this setting.
You may also be interested in...
Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian firm said that the arrival of AbbVie’s rival Skyrizi hasn’t adversely impacted its formulary position.
India’s biggest generics company cautions that investments to ramp up its specialty business are expected to constrain profit growth over the near term, as a one-off charge cuts fourth-quarter income in half.